Monitor the pace of TRUTAKNA prescription uptake and payer coverage expansion in coming quarters, as well as the FDA's review of the sBLA for full approval expected in mid-2027. The company's cash runway and ability to manage launch-related SG&A spending will be key to watch.
Drug in focus
VERA drug pipeline →TRUTAKNA
▲ Bullish Named in this press release- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
- Next catalyst
- None dated
What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $29.79entry
- T+1 · 8d ago +2.77%α +0.40% · $30.61
- T+5 · 4d ago −5.66%α −8.25% · $28.10
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Vera Therapeutics reported Q3 2026 net product revenue of $10.3 million from the initial TRUTAKNA launch following July 7 accelerated FDA approval, with approximately 700 Patient Start Forms received to date. The net loss was $93.7 million ($1.30 per share), wider than the consensus estimate of a $1.62 loss per share, driven by $61.4 million in SG&A expenses for the commercial launch. The company also completed an sBLA submission for full FDA approval, with a decision expected in mid-2027.
Key Financial Metrics
Key Facts
- Q3 2026 net product revenue of $10.3 million from TRUTAKNA launch
- Approximately 700 Patient Start Forms received since July 7 accelerated approval
- Net loss of $93.7 million ($1.30 per share) vs consensus estimate of $-1.62 per share
- sBLA submitted for full FDA approval of TRUTAKNA in primary IgAN, decision expected mid-2027
- Cash, cash equivalents and marketable securities of $384 million as of September 30, 2026; pro forma $459 million after $75 million debt draw in October
- ORIGIN 3 final efficacy data showed annualized eGFR slope of -0.6 vs -5.6 for placebo (p<0.0001) and 76% risk reduction in composite kidney disease progression
Financial Impact
First product revenue of $10.3 million in Q3 2026, compared to zero in prior year; net loss of $93.7 million vs $80.3 million in Q3 2025; cash position of $384 million plus $75 million drawn in October
Risk Factors
- TRUTAKNA is currently approved under accelerated approval; full approval is contingent on confirmatory trial results and FDA review
- Commercial launch expenses are high ($61.4M SG&A in Q3) and may pressure cash runway despite $459M pro forma cash
- Competition from other IgAN therapies and potential payer coverage limitations could affect revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396989 |
Track record
25 reports on VERA
13 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Viewing Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers